Prognostic Biomarkers for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) affects approximately half a million patients worldwide and is the most rapidly increasing cause of cancer death in the United States owing to the lack of effective treatment options for advanced disease . Numerous lines of clinical and histopathologic evidence suggest that HCC is a heterogeneous disease, but a coherent molecular explanation for this heterogeneity has yet to be reported . Due to the phenotypic and molecular diversity of HCC, it is a challenge to determine a patient’s prognosis . It would be ideal to increase monitoring of patients with poor prognosis. Thus the inability to accurately predict prognosis leads to excessive or insufficient time spent following patients, resulting in unnecessary anxiety and cost for patients, and inefficient allocation of resources for hospitals.
- 4.Forner, A., Llovet, J. M., & Bruix, J. (2012). Hepatocellular carcinoma. Lancet, 379(1245–125), 5.Google Scholar
- 13.Villanueva, A., Hoshida, Y., Battison, C., et al. (2011). Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology, 140(1501–1512), e1502.Google Scholar
- 14.Hoshida, Y., Villanueva, A., Sangiovanni, A., et al. Prognostic gene-expression signature for patients with hepatitis C-Related early stage cirrhosis. Gastroentology.Google Scholar
- 15.Clavien, P. A., Lesurtel, M., Bossuyt, P. M., et al. (2012). Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report. Lancet Oncology 13, e11–e22.Google Scholar
- 17.Albain, K. S., Barlow, W. E., Shak, S., et al. (2010). Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomized trial. Lancet Oncology, 11, 55–65.CrossRefGoogle Scholar
- 18.Cardoso, F., Van’t Veer, L., Rutgers, E., et al. (2008). Clinical application of the 70-gene profile: The MINDACT trial. Journal of Clinical Oncology 26, 729–735.Google Scholar